Galderma`s clarifies aj burnett major brands autographed photos examines are: Differin® (adapalene), the company`s first home-grown product indicated for topicaltreatment of acne, Epiduo® (adapalene and benzoyl peroxide / acne),Rozex®/MetroGel® 1% (metronidazole / rosacea), Oracea® (doxycycline / rosacea),Clobex® (clobetasol propionate / psoriasis), Tri-Luma® (hydroquinone, tretinoin,fluocinolone acetonide / pigmentary disorders), Loceryl® (amorolfine /onychomycosis), Azzalure® / Dysport® (botulinum toxin type A / glabellar lines) and Cetaphil®(therapeutic skin care line) The Company`s international website is. In 2008, Galderma had global revenues of 854 million euros.With a main research and development center in Sophia Antipolis, France,Galderma has one of the largest R&D facilities devoted exclusively todermatology. The Company is present in 65countries with more than 2900 employees (including 1000 medical salesrepresentatives). Galderma`s expertise covers a broad spectrum of skin, hairand nail diseases, with a focus on acne, rosacea, psoriasis andsteroid-responsive dermatosis, onychomycosis, pigmentary disorders, skin cancerand medical solutions for skin senescence. About GaldermaGalderma, created in 1981 as a joint venture between Nestlé and L`Oréal, is aglobal leading pharmaceutical company dedicated to the research, development andmarketing of innovative therapeutic, corrective and aesthetic solutions fordermatology patients. In addition, Galderma will pay royalties on net sales toIpsen.
Ipsen will manufacture and supply Galderma`s finished product at afixed supply price autographed baseball . Last December 2007 Ipsen and Galderma entered into anotherpartnership for the exclusive promotion and distribution of Ipsen`s botulinumtoxin type A product, for use in aesthetic medicine and dermatologicalindications in Brazil, Argentina and Paraguay.Galderma will pay up to ?20 million to Ipsen upon the achievement of certainmilestones, including local market approvals and product launches in certainterritories baseball managers . Inaddition, Galderma has also been granted first rights of negotiation foraesthetic indications in the rest of the world, excluding the United States,Canada and Japan baseball tickets . This agreement includes theEuropean Union and certain territories of the Middle East and Eastern Europe buy tickets .
Under the terms of thisagreement, Galderma has been granted by Ipsen exclusive rights to develop,promote and distribute Azzalure®, a customized dosage of its botulinum toxintype A product Dysport®, for aesthetic indications autographed baseballs . About the agreementThis announcement represents the latest developments in a partnershipestablished in 2007 between Galderma and Ipsen autographed photos . In Europe, the average annual growth expected between2009 and 2012 is 13.2%, driven by dramatic rise in the popularity of easy to useand non invasive treatments, such as botulinum toxin procedures, that alreadyrepresent 60% of specialist procedures in Europe baseball managers . The world Corrective and Aesthetic marketplace was estimated in 2008 to 5billion euros by Medical Insight (report published last year) Its growth couldreach up to 10% in 2009 . Azzalure® is the latest product in our expanding range ofdermatology treatments and emphasizes our commitment to the future ofdermatology", said Marc Wannhoff, General Manager of Galderma Germany. Patients can look forward to benefitingfrom Galderma`s years of experience in dermatology, and our commitment toproviding the highest standards of medical education and training to healthcareprofessionals.
Comments are closed.